GTB-3650 TriKE for high-risk MDS and relapsed AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new immunotherapy called GTB-3650 TriKE for people with high-risk MDS or AML that has come back or not responded to treatment. It aims to boost your immune system to fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-risk MDS, treatment-related MDS, or relapsed/refractory AML.
- Your blood tests show enough lymphocytes (immune cells) or NK cells.
- Your cancer cells in the blood are not too high at the start of treatment.
- You are well enough to do daily activities (Karnofsky score 70% or higher).
- Your organs (heart, lungs, liver, kidneys) are working well enough.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called RPT1G for adults with acute myeloid leukemia or high-risk myelodysplastic syndromes that have not responded to standard treatments. The goal is to see if the drug is safe and if it shows signs of helping control the disease.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This study tests a new intravenous drug, TCB008, for people with acute myeloid leukemia (AML) or MDS/AML that has returned or not responded to previous treatments. The goal is to see if it is safe and if it can help control the cancer.
This Phase 1 study tests BTX-A51 in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It’s designed to see if the treatment can be given safely and to learn how it works in people whose standard treatments have not helped or are no longer an option.
This trial tests a new drug called GEN3018 for people with acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS) that has come back or not responded to standard treatments. It aims to see if the drug is safe and effective.
This trial tests an oral investigational drug (GLB-001) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or hasn't responded to other treatments. The goal is to see if it's safe and effective for those who have run out of standard options.
Hear when a new Myeloid Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.